
Annual report 2024
added 03-14-2026
Grifols, S.A. Net Income 2011-2026 | GRFS
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Grifols, S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 265 M | 619 M | 986 M | 857 M | 730 M | 881 M | 849 M | 712 M | 653 M | 521 M | 110 M |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 986 M | 110 M | 653 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M | ||
|
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | ||
|
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | ||
|
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M | ||
|
Aileron Therapeutics
ALRN
|
-62.9 M | - | 10.36 % | $ 9.8 M | ||
|
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | ||
|
Cabaletta Bio
CABA
|
-168 M | $ 2.82 | 1.44 % | $ 283 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | ||
|
AgeX Therapeutics
AGE
|
-19.2 M | - | -10.17 % | $ 12.2 K | ||
|
Aptinyx
APTX
|
-64.8 M | - | -39.0 % | $ 4.57 M | ||
|
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | ||
|
Esperion Therapeutics
ESPR
|
-22.7 M | $ 2.85 | 3.26 % | $ 592 M | ||
|
Acasti Pharma
ACST
|
-9.57 M | - | 4.01 % | $ 150 M | ||
|
Equillium
EQ
|
-22.4 M | $ 2.06 | - | $ 118 M | ||
|
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - | ||
|
Adverum Biotechnologies
ADVM
|
-131 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-26.2 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M | ||
|
Avenue Therapeutics
ATXI
|
-11.7 M | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
-221 M | $ 1.29 | -3.01 % | $ 329 M | ||
|
Stoke Therapeutics
STOK
|
-6.88 M | $ 33.7 | -0.27 % | $ 2 B | ||
|
Atreca
BCEL
|
-97.2 M | - | -11.76 % | $ 5.79 M | ||
|
BeiGene, Ltd.
BGNE
|
287 M | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
-212 M | - | - | $ 546 M | ||
|
Heron Therapeutics
HRTX
|
-20.2 M | $ 0.83 | 3.62 % | $ 138 M | ||
|
BioDelivery Sciences International
BDSI
|
84.9 M | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
-119 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
-132 M | - | - | $ 3.74 B | ||
|
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | ||
|
Avid Bioservices
CDMO
|
-141 M | - | - | $ 789 M | ||
|
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | ||
|
Savara
SVRA
|
-119 M | $ 5.25 | -0.57 % | $ 1.17 B | ||
|
China SXT Pharmaceuticals
SXTC
|
-3.3 M | $ 1.32 | -5.2 % | $ 1.88 M | ||
|
Bellerophon Therapeutics
BLPH
|
-19.8 M | - | -74.18 % | $ 955 K | ||
|
Kala Pharmaceuticals
KALA
|
-38.5 M | $ 0.2 | -6.67 % | $ 759 K | ||
|
Tarsus Pharmaceuticals
TARS
|
-66.4 M | $ 67.2 | 0.36 % | $ 2.81 B | ||
|
CRISPR Therapeutics AG
CRSP
|
-582 M | $ 47.55 | 0.98 % | $ 4.28 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
-33.5 M | $ 4.45 | -1.77 % | $ 853 M | ||
|
AIkido Pharma
AIKI
|
-14.7 M | - | 1.93 % | $ 17.4 M | ||
|
Allakos
ALLK
|
-186 M | - | - | $ 28.6 M | ||
|
Brickell Biotech
BBI
|
-5.69 M | - | -5.38 % | $ 6.06 M | ||
|
Allena Pharmaceuticals
ALNA
|
-48.7 M | - | 3.16 % | $ 1.9 M |